Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric H Rubin

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Developing precision medicine in a global worldEric H Rubin, Jeffrey D Allen, Jan A Nowak, et al.
Contemporary Clinical Trials|October 3, 2017
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentCong Chen, Keaven Anderson, Devan V Mehrotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trialJoseph Aisner, Rita Musanti, Stephanie Beers, et al.
Journal of Clinical Pharmacology|September 19, 2017
Dose Finding Versus Speed in Seamless Immuno-Oncology Drug DevelopmentKapil Mayawala, Archie Tse, Eric H Rubin, et al.
Experimental Cell Research|June 27, 2002
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodiesZeshaan A Rasheed, Ahamed Saleem, Yaniv Ravee, et al.
Cancer Immunology Research|December 3, 2017
Report on the Third FDA-AACR Oncology Dose-Finding WorkshopLeisha A Emens, Rene Bruno, Eric H Rubin, et al.
Contemporary Clinical Trials|July 2, 2019
Optimal two-stage designs for exploratory basket trialsHeng Zhou, Fang Liu, Cai Wu, et al.
Contemporary Clinical Trials|March 26, 2017
How many tumor indications should be initially screened in development of next generation immunotherapies?Cong Chen, Qiqi Deng, Linchen He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Biochemistry|December 5, 2008
Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activityHye-Jin Park, Haiyan Zheng, Diptee Kulkarni, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Developing precision medicine in a global worldEric H Rubin, Jeffrey D Allen, Jan A Nowak, et al.
Contemporary Clinical Trials|October 3, 2017
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentCong Chen, Keaven Anderson, Devan V Mehrotra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trialJoseph Aisner, Rita Musanti, Stephanie Beers, et al.
Journal of Clinical Pharmacology|September 19, 2017
Dose Finding Versus Speed in Seamless Immuno-Oncology Drug DevelopmentKapil Mayawala, Archie Tse, Eric H Rubin, et al.
Experimental Cell Research|June 27, 2002
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodiesZeshaan A Rasheed, Ahamed Saleem, Yaniv Ravee, et al.
Cancer Immunology Research|December 3, 2017
Report on the Third FDA-AACR Oncology Dose-Finding WorkshopLeisha A Emens, Rene Bruno, Eric H Rubin, et al.
Contemporary Clinical Trials|July 2, 2019
Optimal two-stage designs for exploratory basket trialsHeng Zhou, Fang Liu, Cai Wu, et al.
Contemporary Clinical Trials|March 26, 2017
How many tumor indications should be initially screened in development of next generation immunotherapies?Cong Chen, Qiqi Deng, Linchen He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Biochemistry|December 5, 2008
Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activityHye-Jin Park, Haiyan Zheng, Diptee Kulkarni, et al.
Pageof 7